Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05853965
Title Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma (BELI(E)VE)
Acronym BELI(E)VE
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Universitatsklinikum Hamburg-Eppendorf
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.